New onset or exacerbation of pre-existing psoriasis after therapeutic TNF-α inhibition is a
well-described phenomenon. Over the last two decades, similar cases of paradoxical …

The treatment of severe psoriasis in patients with concomitant hepatitis-C virus infection is
quite difficult because several systemic anti-psoriatic drugs are contraindicated owing to …

Background Psoriasis exhibits several extracutaneous manifestations. Little is known about
hepatic parameters specifically associated with psoriasis. Objectives To study whether …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

OBJECTIVES: The paradoxical observation that antitumor necrosis factor (anti-TNF) agents
are capable of inducing psoriasis and psoriasiform skin lesions while also being therapy for …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …

Sažetak Tumor necrosis factor alpha inhibitors revolutionized the management of patients
affected by autoimmune diseases such as inflammatory bowel diseases, rheumatoid …

Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …

We describe a case of previously unreported autoimmune hepatitis and lupus‐like
syndrome induced by infliximab treatment for chronic plaque psoriasis. The condition …

Up to date, in literature, it is still debated the role of anti-tumor necrosis factors (TNF)-α
treatments in hepatitis C virus (HCV) patients. TNF-α performs a lot of functions, it is an …